20231130-西南证券-康诺亚-B-02162.HK-CM310申报上市在即_自免领域龙头_28页_4mb

Summary of Canco Pharmaceutical (2162HK) Research Report

Company Overview

Canco is a Hong Kong-listed biopharmaceutical company specializing in autoimmune diseases and oncology, with a robust R&D pipeline including nine clinical candidates. The company, founded in 2016 and led by experienced management, focuses on innovative treatments for conditions like atopic dermatitis and cancer. Key partnerships, such as with Shiyao Group and AstraZeneca, aim to accelerate commercialization of its products.

Key Recommendations and Products

• CM310 (IL-4Rα antibody): Expected to seek NDA approval in late 2023 for atopic dermatitis (AD) and chronic rhinosinusitis (CRSwNP). In clinical trials, it demonstrated superiority over dupilumab in AD, with high rates of efficacy endpoints being met. Potential as a best-in-class BIC drug.
• CMG901 (Claudin182 ADC): Partnered exclusively with AstraZeneca for global development; Phase I trials show strong efficacy in gastric cancer (e.g., 33% ORR in refractory patients). Expected to enter Phase III in 2024, with commercial potential in gastric and pancreatic cancers.
• CM338 (MASP2 inhibitor): In Phase II for IgA nephropathy; shows high affinity and potency in inhibiting complement activation, indicating best-in-class potential.
• Other products: CM326 (TSLP inhibitor) for asthma and inflammatory diseases is in Phase II; CM338 targets IgA nephropathy; CMG901 focuses on gastric cancer.

Financial Predictions

Based on CM310 and CMG901 advancements, the company's revenue is projected at 33 billion HKD in 2023, growing to 15 billion HKD in 2025 and 27 billion HKD in 2026. Key assumptions include successful NDA approvals and market penetration growth.

Risks

R&D uncertainties, including potential delays in trials; commercial risks like competition and pricing pressures; policy risks in the healthcare sector affecting drug availability and market growth.